Illumina, Inc. (ILMN)Healthcare | Diagnostics & Research | San Diego, United States | NasdaqGS
215.59 USD
-12.10
(-5.314%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 215.70 +0.11 (0.051%) ⇧ (Aug. 28, 2026, 7:58 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:05 a.m. EDT
Despite robust ROE and positive revenue growth, the stock has endured four consecutive years of price declines, capping its long-term investment appeal. Short-term momentum is strong, trading near its 52-week high with significant call volume above current levels. No dividend yield is available. Options flow suggests a mix of bullish bets and downside hedging, creating a tense environment where technicals favor a breakout but the multi-year downtrend warns of structural weakness. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.035831 |
| AutoARIMA | 0.069207 |
| AutoETS | 0.098787 |
| MSTL | 0.102027 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 3.04 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.692 |
| Excess Kurtosis | -0.58 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 89.042 |
| Revenue per Share | 29.566 |
| Market Cap | 32,554,088,448 |
| Trailing P/E | 42.52 |
| Forward P/E | 35.36 |
| Beta | 1.46 |
| Profit Margins | 18.34% |
| Website | https://www.illumina.com |
As of Aug. 22, 2026, 4:05 a.m. EDT: Options activity indicates a mixed sentiment with bullish positioning concentrated in the 230-250 strike range for near-term expirations, while defensive put volume clusters around the 170-190 range. Implied volatility remains elevated at the money (~53-55%), with significant premiums priced for deep in-the-money strikes, suggesting a market anticipating significant moves in either direction but leaning slightly toward upside continuation given the call OI concentration above current price.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.3276427 |
| Address1 | 5,200 Illumina Way |
| All Time High | 540.6323 |
| All Time Low | 0.831712 |
| Ask | 225.91 |
| Ask Size | 1 |
| Audit Risk | 2 |
| Average Analyst Rating | 2.5 - Buy |
| Average Daily Volume10 Day | 1,829,340 |
| Average Daily Volume3 Month | 1,980,440 |
| Average Volume | 1,980,440 |
| Average Volume10Days | 1,829,340 |
| Beta | 1.464 |
| Bid | 204.6 |
| Bid Size | 1 |
| Board Risk | 1 |
| Book Value | 18.795 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 215.59 |
| Current Ratio | 1.796 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 225.09 |
| Day Low | 214.61 |
| Debt To Equity | 89.042 |
| Display Name | Illumina |
| Earnings Call Timestamp End | 1,785,443,400 |
| Earnings Call Timestamp Start | 1,785,443,400 |
| Earnings Growth | -0.094 |
| Earnings Quarterly Growth | -0.119 |
| Earnings Timestamp | 1,785,441,600 |
| Earnings Timestamp End | 1,793,304,000 |
| Earnings Timestamp Start | 1,793,304,000 |
| Ebitda | 1,155,000,064 |
| Ebitda Margins | 0.25701 |
| Enterprise To Ebitda | 29.362 |
| Enterprise To Revenue | 7.546 |
| Enterprise Value | 33,913,090,048 |
| Eps Current Year | 5.35631 |
| Eps Forward | 6.09635 |
| Eps Trailing Twelve Months | 5.07 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 858 202 4766 |
| Fifty Day Average | 192.3874 |
| Fifty Day Average Change | 23.20259 |
| Fifty Day Average Change Percent | 0.12060348 |
| Fifty Two Week Change Percent | 132.76427 |
| Fifty Two Week High | 231.81 |
| Fifty Two Week High Change | -16.220001 |
| Fifty Two Week High Change Percent | -0.0699711 |
| Fifty Two Week Low | 88.0 |
| Fifty Two Week Low Change | 127.59 |
| Fifty Two Week Low Change Percent | 1.4498863 |
| Fifty Two Week Range | 88.0 - 231.81 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 964,791,000,000 |
| Float Shares | 149,156,290 |
| Forward Eps | 6.09635 |
| Forward P E | 35.36378 |
| Free Cashflow | 797,625,024 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 8,600 |
| Fullday Change | -12.1 |
| Fullday Change Percent | -5.31425 |
| Fullday Price | 215.7 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.67934996 |
| Gross Profits | 3,052,999,936 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00196 |
| Held Percent Institutions | 1.05851 |
| Implied Shares Outstanding | 151,000,000 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Ir Website | http://investor.illumina.com/phoenix.zhtml?c=121127&p=IROL-irhome |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,766,880,000 |
| Last Split Date | 1,719,273,600 |
| Last Split Factor | 1,028:1000 |
| Long Business Summary | Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California. |
| Long Name | Illumina, Inc. |
| Market | us_market |
| Market Cap | 32,554,088,448 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_29753 |
| Most Recent Quarter | 1,782,604,800 |
| Net Income To Common | 824,000,000 |
| Next Fiscal Year End | 1,798,416,000 |
| Non Diluted Market Cap | 34,381,190,000 |
| Number Of Analyst Opinions | 19 |
| Open | 225.0 |
| Operating Cashflow | 1,095,000,064 |
| Operating Margins | 0.21139 |
| Overall Risk | 2 |
| Payout Ratio | 0.0 |
| Peg Ratio | 3.19 |
| Phone | 858 202 4500 |
| Post Market Change | 0.11000061 |
| Post Market Change Percent | 0.05102306 |
| Post Market Price | 215.7 |
| Post Market Time | 1,787,961,509 |
| Previous Close | 227.69 |
| Price Eps Current Year | 40.249725 |
| Price Hint | 2 |
| Price To Book | 11.470604 |
| Price To Sales Trailing12 Months | 7.2439003 |
| Profit Margins | 0.18336001 |
| Quick Ratio | 1.248 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.45 |
| Region | US |
| Regular Market Change | -12.1 |
| Regular Market Change Percent | -5.31425 |
| Regular Market Day High | 225.09 |
| Regular Market Day Low | 214.61 |
| Regular Market Day Range | 214.61 - 225.09 |
| Regular Market Open | 225.0 |
| Regular Market Previous Close | 227.69 |
| Regular Market Price | 215.59 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 1,791,493 |
| Return On Assets | 0.086660005 |
| Return On Equity | 0.32339 |
| Revenue Growth | 0.094 |
| Revenue Per Share | 29.566 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 151,000,000 |
| Shares Percent Shares Out | 0.0627 |
| Shares Short | 9,464,776 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 8,752,414 |
| Short Name | Illumina, Inc. |
| Short Percent Of Float | 0.1026 |
| Short Ratio | 5.0 |
| Source Interval | 15 |
| State | CA |
| Symbol | ILMN |
| Target High Price | 230.0 |
| Target Low Price | 113.0 |
| Target Mean Price | 198.89474 |
| Target Median Price | 211.0 |
| Total Cash | 1,168,000,000 |
| Total Cash Per Share | 7.735 |
| Total Debt | 2,527,000,064 |
| Total Revenue | 4,494,000,128 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 5.07 |
| Trailing P E | 42.522682 |
| Trailing Peg Ratio | 3.2302 |
| Triggerable | 1 |
| Two Hundred Day Average | 149.06026 |
| Two Hundred Day Average Change | 66.52974 |
| Two Hundred Day Average Change Percent | 0.4463278 |
| Type Disp | Equity |
| Volume | 1,791,493 |
| Website | https://www.illumina.com |
| Zip | 92,122 |